Clinical Trial Update: A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland

View source ↗

Summary

Takeda-sponsored clinical study evaluating lanadelumab for hereditary angioedema (HAE) in Poland has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Takhzyro (lanadelumab)

Snippet

Sponsor: Takeda | Conditions: Hereditary Angioedema (HAE) | Status: COMPLETED